EKF Diagnostics Holdings PLC (LON:EKF) said it expects to beat already upgraded financial forecasts thanks ostensibly to booming US demand for its sample collection devices, which deactivate viruses and bacteria.
It said it had received an additional £7.7mln order for its PrimeStore MTM product from Longhorn Vaccines and Diagnostics for the two months to July. It had already landed a £2.5mln contract from Longhorn.
The additional contribution means first-half sales will be at least £25mln, up from £21.44mln a year earlier, while underlying earnings (EBITDA) are forecast to be around £7.5mln, a rise of 34%.
Looking ahead, EKF said: “The US Administration is emphasising testing as the most appropriate means to contain the virus. In these circumstances, the board expects the second half of the year will see continued momentum and the full-year results will exceed, perhaps considerably, its recently upgraded expectations.”